← Russell 3000 cross-section

ZSQR Z Squared Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-13, not restated
Financials

Scale

Market cap
$233m
Revenue TTM
$3m
Net income TTM
$-22m
Free cash flow
Composite score
Sector rank
#2796

Valuation

P / E
EV / EBITDA
EV / sales
77.8
FCF yield
Earnings yield vs 10-yr
-14.16pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-785.8%
EBITDA margin
-730.4%
ROE
-16.6%
ROIC
-18.9%
Revenue growth
961.2%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
1
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

The co-development and steering committee agreement provides for the governance and economic agreements between the Company and Vy-Gen related of the development of the two Vy-Gen drug product candidates and the revenue sharing related thereto, including each company having a 50% representation on the steering committee and each company receiving 50% of the net revenues related to the Vy-Gen product candidates. The discussion below therefore addresses both periods together, and references to amounts apply to both periods except as otherwise noted. …Z Squared Inc., 10-Q, period ended 2026-06-30, filed 2026-08-13

Read the full passage →